262 related articles for article (PubMed ID: 24390213)
1. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
2. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
3. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
4. A Guide to Pheochromocytomas and Paragangliomas.
Guilmette J; Sadow PM
Surg Pathol Clin; 2019 Dec; 12(4):951-965. PubMed ID: 31672301
[TBL] [Abstract][Full Text] [Related]
5. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
Yeramian A; Sorolla A; Velasco A; Santacana M; Dolcet X; Valls J; Abal L; Moreno S; Egido R; Casanova JM; Puig S; Vilella R; Llombart-Cussac A; Matias-Guiu X; Martí RM
Int J Cancer; 2012 Feb; 130(4):967-78. PubMed ID: 21445974
[TBL] [Abstract][Full Text] [Related]
8. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells.
Ikeda T; Ishii KA; Saito Y; Miura M; Otagiri A; Kawakami Y; Shimano H; Hara H; Takekoshi K
J Pharmacol Sci; 2013; 121(1):67-73. PubMed ID: 23269235
[TBL] [Abstract][Full Text] [Related]
10. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.
Favier J; Igaz P; Burnichon N; Amar L; Libé R; Badoual C; Tissier F; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP
Endocr Pathol; 2012 Mar; 23(1):34-42. PubMed ID: 22183643
[TBL] [Abstract][Full Text] [Related]
11. Targeting NAD
Pang Y; Lu Y; Caisova V; Liu Y; Bullova P; Huynh TT; Zhou Y; Yu D; Frysak Z; Hartmann I; Taïeb D; Pacak K; Yang C
Clin Cancer Res; 2018 Jul; 24(14):3423-3432. PubMed ID: 29636359
[No Abstract] [Full Text] [Related]
12. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R
Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802
[TBL] [Abstract][Full Text] [Related]
14. SDH-related pheochromocytoma and paraganglioma.
Kantorovich V; King KS; Pacak K
Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):415-24. PubMed ID: 20833333
[TBL] [Abstract][Full Text] [Related]
15. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
[TBL] [Abstract][Full Text] [Related]
16. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
[TBL] [Abstract][Full Text] [Related]
17. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
19. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
Moog S; Salgues B; Braik-Djellas Y; Viel T; Balvay D; Autret G; Robidel E; Gimenez-Roqueplo AP; Tavitian B; Lussey-Lepoutre C; Favier J
Endocr Relat Cancer; 2022 May; 29(6):375-388. PubMed ID: 35348472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]